[
  {
    "ts": null,
    "headline": "Big Pharma Avoids Worst-Case Tariff Scenario",
    "summary": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",
    "url": "https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743631415,
      "headline": "Big Pharma Avoids Worst-Case Tariff Scenario",
      "id": 133695061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.",
      "url": "https://finnhub.io/api/news?id=e56792421f40cd13cbd5b94e4465a2bf24427e7b41aded3c7608a2d37bd75b9a"
    }
  },
  {
    "ts": null,
    "headline": "Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
    "summary": "Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.",
    "url": "https://finnhub.io/api/news?id=7c0562153c3a0a24c8e0163dd5e00d1acff00381e6b683704e1d001b43392927",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743625975,
      "headline": "Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
      "id": 133679116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.",
      "url": "https://finnhub.io/api/news?id=7c0562153c3a0a24c8e0163dd5e00d1acff00381e6b683704e1d001b43392927"
    }
  },
  {
    "ts": null,
    "headline": "Primary care firm knownwell joins LillyDirect to offer weight-management services",
    "summary": "Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's direct-to-consumer online healthcare platform, LillyDirect. Patients on LillyDirect will have access to physicians from knownwell for personalized services, knownwell said. The company offers in-person and virtual primary care, nutrition counseling and behavioral health services, covered through patients' insurance.",
    "url": "https://finnhub.io/api/news?id=b85daa67b6fd5a153f9e1f783c36dc23494231170ebc2a46059dc492c3567e88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743621707,
      "headline": "Primary care firm knownwell joins LillyDirect to offer weight-management services",
      "id": 133675918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's direct-to-consumer online healthcare platform, LillyDirect. Patients on LillyDirect will have access to physicians from knownwell for personalized services, knownwell said. The company offers in-person and virtual primary care, nutrition counseling and behavioral health services, covered through patients' insurance.",
      "url": "https://finnhub.io/api/news?id=b85daa67b6fd5a153f9e1f783c36dc23494231170ebc2a46059dc492c3567e88"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Zepbound Offering Won’t Bring Needed Sales Boom, Analysts Say",
    "summary": "Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.",
    "url": "https://finnhub.io/api/news?id=dd36105d6190d2d1254e5d8f803f0ed0e88f7e1384aafb2a41f748400a0a8a3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743617520,
      "headline": "Hims & Hers Zepbound Offering Won’t Bring Needed Sales Boom, Analysts Say",
      "id": 133675920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, will struggle to meet its revenue goal.",
      "url": "https://finnhub.io/api/news?id=dd36105d6190d2d1254e5d8f803f0ed0e88f7e1384aafb2a41f748400a0a8a3f"
    }
  },
  {
    "ts": null,
    "headline": "Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
    "summary": "Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.",
    "url": "https://finnhub.io/api/news?id=c6af30fc41669b4c2f928a17a02f2a221c6afd74fa91c6ef29716abd94d981f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743609235,
      "headline": "Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
      "id": 133669378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.",
      "url": "https://finnhub.io/api/news?id=c6af30fc41669b4c2f928a17a02f2a221c6afd74fa91c6ef29716abd94d981f8"
    }
  },
  {
    "ts": null,
    "headline": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
    "summary": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
    "url": "https://finnhub.io/api/news?id=611d6c8d7611d0acc68c83eed246c9f8d45eefbfc4007a723fb61da60186c604",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743601380,
      "headline": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
      "id": 133669379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
      "url": "https://finnhub.io/api/news?id=611d6c8d7611d0acc68c83eed246c9f8d45eefbfc4007a723fb61da60186c604"
    }
  },
  {
    "ts": null,
    "headline": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
    "summary": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
    "url": "https://finnhub.io/api/news?id=1c51ec2a04ac175f6294f5ba97b2649a1cc9e9032ba4698ec15736e9697c440b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743594600,
      "headline": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
      "id": 133670047,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Drug Industry Offers Tepid Pushback to Kennedy’s FDA Job Cuts",
      "url": "https://finnhub.io/api/news?id=1c51ec2a04ac175f6294f5ba97b2649a1cc9e9032ba4698ec15736e9697c440b"
    }
  },
  {
    "ts": null,
    "headline": "Why April Could Be a Huge Month for Eli Lilly Stock",
    "summary": "Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion.  Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.  Investors are beginning to scoff at its expensive price tag, with Eli Lilly trading at more than 70 times its trailing earnings.",
    "url": "https://finnhub.io/api/news?id=cc10b6c3649522d05974a57af0638b28ef28fdc6c881ad8d83a33d1ae92bb95b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743590760,
      "headline": "Why April Could Be a Huge Month for Eli Lilly Stock",
      "id": 133666095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion.  Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.  Investors are beginning to scoff at its expensive price tag, with Eli Lilly trading at more than 70 times its trailing earnings.",
      "url": "https://finnhub.io/api/news?id=cc10b6c3649522d05974a57af0638b28ef28fdc6c881ad8d83a33d1ae92bb95b"
    }
  },
  {
    "ts": null,
    "headline": "Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?",
    "summary": "Tobacco giant Altria (NYSE: MO) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%.  Meanwhile, pharma company Eli Lilly (NYSE: LLY) offers a much lower yield of less than 1%, but its dividend growth rate has been far more impressive.  Which stock is the better buy if your priority is to collect a lot of dividend income?",
    "url": "https://finnhub.io/api/news?id=295105eec3d3c23d8fd59da0964391672ce746007e4a7860bbf9e4467bd6c861",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743584760,
      "headline": "Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?",
      "id": 133666096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tobacco giant Altria (NYSE: MO) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%.  Meanwhile, pharma company Eli Lilly (NYSE: LLY) offers a much lower yield of less than 1%, but its dividend growth rate has been far more impressive.  Which stock is the better buy if your priority is to collect a lot of dividend income?",
      "url": "https://finnhub.io/api/news?id=295105eec3d3c23d8fd59da0964391672ce746007e4a7860bbf9e4467bd6c861"
    }
  },
  {
    "ts": null,
    "headline": "Compounding Problems: Recent Decisions On Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement And Private Intellectual Property Rights",
    "summary": "Earlier this month, a federal district court denied the Outsourcing Facilities Association's preliminary injunction motion, which sought to preclude FDA from taking enforcement action against...",
    "url": "https://finnhub.io/api/news?id=80066120837ab3751297b83c67262e0924eed3064dd374a719b9c193dcc26690",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743567068,
      "headline": "Compounding Problems: Recent Decisions On Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement And Private Intellectual Property Rights",
      "id": 133664408,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Earlier this month, a federal district court denied the Outsourcing Facilities Association's preliminary injunction motion, which sought to preclude FDA from taking enforcement action against...",
      "url": "https://finnhub.io/api/news?id=80066120837ab3751297b83c67262e0924eed3064dd374a719b9c193dcc26690"
    }
  }
]